Ocular surface disturbance in patients after acute COVID‐19

Background We investigated the ocular surface disturbances in COVID‐19 patients discharged from the hospital. Methods One hundred and seventy‐nine eyes of 109 healthy participants and 456 eyes of 228 post‐COVID‐19 patients received comprehensive eye examinations; the latter were interviewed with que...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & experimental ophthalmology 2022-05, Vol.50 (4), p.398-406
Hauptverfasser: Wan, Kelvin H., Lui, Grace C. Y., Poon, Ken C. F., Ng, Susanna S. S., Young, Alvin L., Hui, David S. C., Tham, Clement C. Y., Chan, Paul K. S., Pang, Chi Pui, Chong, Kelvin K. L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 406
container_issue 4
container_start_page 398
container_title Clinical & experimental ophthalmology
container_volume 50
creator Wan, Kelvin H.
Lui, Grace C. Y.
Poon, Ken C. F.
Ng, Susanna S. S.
Young, Alvin L.
Hui, David S. C.
Tham, Clement C. Y.
Chan, Paul K. S.
Pang, Chi Pui
Chong, Kelvin K. L.
description Background We investigated the ocular surface disturbances in COVID‐19 patients discharged from the hospital. Methods One hundred and seventy‐nine eyes of 109 healthy participants and 456 eyes of 228 post‐COVID‐19 patients received comprehensive eye examinations; the latter were interviewed with questionnaires on ocular symptoms before and after COVID‐19 diagnosis. Associations of ocular surface manifestations with virological and ophthalmic parameters were evaluated by multivariable mixed linear or logistic regression models. Results Mean interval between COVID‐19 diagnosis and ophthalmic evaluation was 52.23 ± 16.12 days. The severity of meibomian gland dysfunction (MGD) based on clinical staging was higher in post‐COVID‐19 than healthy eyes (1.14 ± 0.67 vs. 0.92 ± 0.68, p = 0.002) and so was ocular surface staining score (0.60 ± 0.69 vs. 0.49 ± 0.68, p = 0.044). Patients requiring supplementary oxygen during hospitalisation had shorter tear break‐up time (β −1.63, 95% CI ‐2.61 to −0.65). Cycle threshold (Ct) value from upper respiratory samples (inversely correlated with viral load) at diagnosis had an OR = 0.91 (95% CI 0.84–0.98) with new ocular surface symptoms 4 weeks after diagnosis. The presence of ocular surface symptoms 1 week prior to COVID‐19 diagnosis showed an OR of 20.89 (95% CI 6.35–68.66) of persistent or new ocular symptoms 4 weeks afterward. Conclusions MGD and ocular surface staining are more common and severe in post‐COVID‐19 patients. Patients with higher viral loads have greater risks of ocular surface symptoms. Patients requiring supplementary oxygen are more likely to show tear film instability. Ocular surface evaluation should be considered 1–3 months following hospital discharge for any COVID‐19 patient.
doi_str_mv 10.1111/ceo.14066
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9111848</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2633896501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4436-5c23d6ddee1b6a02eeeb734e41ce04e3117fac0e43594ec36443ab76ce9338053</originalsourceid><addsrcrecordid>eNp1kUFOwzAQRS0EoqWw4AIoEhtYpLVjx0kWIKFQoFKlboCt5TgTcJUmxU5A3XEEzshJMKRUgIQ3M5Kf_3zPR-iQ4CFxZ6SgHhKGOd9CfcJY4Cc4ItvrnjPMemjP2jnGOAwo30U9GgYkJpT10dlMtaU0nm1NIRV4ubZNazJZuV5X3lI2GqrGerJowHhStQ146ex-cvn--kaSfbRTyNLCwboO0N3V-Da98aez60l6MfUVY5T7oQpozvMcgGRc4gAAsogyYEQBZkAJidxwDIyGCQNFuXsls4grSCiNcUgH6LzTXbbZAnLlLBlZiqXRC2lWopZa_L6p9KN4qJ9F4tYTs9gJnKwFTP3Ugm3EQlsFZSkrqFsrAu4GJTzExKHHf9B53ZrKfc9RUUQoxiRw1GlHKVNba6DYmCFYfIYiXCjiKxTHHv10vyG_U3DAqANedAmr_5VEOp51kh8O0ZXK</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2677130012</pqid></control><display><type>article</type><title>Ocular surface disturbance in patients after acute COVID‐19</title><source>Wiley Online Library - AutoHoldings Journals</source><creator>Wan, Kelvin H. ; Lui, Grace C. Y. ; Poon, Ken C. F. ; Ng, Susanna S. S. ; Young, Alvin L. ; Hui, David S. C. ; Tham, Clement C. Y. ; Chan, Paul K. S. ; Pang, Chi Pui ; Chong, Kelvin K. L.</creator><creatorcontrib>Wan, Kelvin H. ; Lui, Grace C. Y. ; Poon, Ken C. F. ; Ng, Susanna S. S. ; Young, Alvin L. ; Hui, David S. C. ; Tham, Clement C. Y. ; Chan, Paul K. S. ; Pang, Chi Pui ; Chong, Kelvin K. L.</creatorcontrib><description>Background We investigated the ocular surface disturbances in COVID‐19 patients discharged from the hospital. Methods One hundred and seventy‐nine eyes of 109 healthy participants and 456 eyes of 228 post‐COVID‐19 patients received comprehensive eye examinations; the latter were interviewed with questionnaires on ocular symptoms before and after COVID‐19 diagnosis. Associations of ocular surface manifestations with virological and ophthalmic parameters were evaluated by multivariable mixed linear or logistic regression models. Results Mean interval between COVID‐19 diagnosis and ophthalmic evaluation was 52.23 ± 16.12 days. The severity of meibomian gland dysfunction (MGD) based on clinical staging was higher in post‐COVID‐19 than healthy eyes (1.14 ± 0.67 vs. 0.92 ± 0.68, p = 0.002) and so was ocular surface staining score (0.60 ± 0.69 vs. 0.49 ± 0.68, p = 0.044). Patients requiring supplementary oxygen during hospitalisation had shorter tear break‐up time (β −1.63, 95% CI ‐2.61 to −0.65). Cycle threshold (Ct) value from upper respiratory samples (inversely correlated with viral load) at diagnosis had an OR = 0.91 (95% CI 0.84–0.98) with new ocular surface symptoms 4 weeks after diagnosis. The presence of ocular surface symptoms 1 week prior to COVID‐19 diagnosis showed an OR of 20.89 (95% CI 6.35–68.66) of persistent or new ocular symptoms 4 weeks afterward. Conclusions MGD and ocular surface staining are more common and severe in post‐COVID‐19 patients. Patients with higher viral loads have greater risks of ocular surface symptoms. Patients requiring supplementary oxygen are more likely to show tear film instability. Ocular surface evaluation should be considered 1–3 months following hospital discharge for any COVID‐19 patient.</description><identifier>ISSN: 1442-6404</identifier><identifier>EISSN: 1442-9071</identifier><identifier>DOI: 10.1111/ceo.14066</identifier><identifier>PMID: 35218134</identifier><language>eng</language><publisher>Melbourne: John Wiley &amp; Sons Australia, Ltd</publisher><subject>COVID-19 ; Diagnosis ; Eye ; Eye examinations ; meibomian gland dysfunction ; ocular surface ; Original ; ORIGINAL ARTICLES ; Oxygen ; Patients ; Regression analysis ; tear break up time</subject><ispartof>Clinical &amp; experimental ophthalmology, 2022-05, Vol.50 (4), p.398-406</ispartof><rights>2022 Royal Australian and New Zealand College of Ophthalmologists.</rights><rights>2022 Royal Australian and New Zealand College of Ophthalmologists</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4436-5c23d6ddee1b6a02eeeb734e41ce04e3117fac0e43594ec36443ab76ce9338053</citedby><cites>FETCH-LOGICAL-c4436-5c23d6ddee1b6a02eeeb734e41ce04e3117fac0e43594ec36443ab76ce9338053</cites><orcidid>0000-0003-0307-2256 ; 0000-0003-2587-1323</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fceo.14066$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fceo.14066$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,315,781,785,886,1418,27929,27930,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35218134$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wan, Kelvin H.</creatorcontrib><creatorcontrib>Lui, Grace C. Y.</creatorcontrib><creatorcontrib>Poon, Ken C. F.</creatorcontrib><creatorcontrib>Ng, Susanna S. S.</creatorcontrib><creatorcontrib>Young, Alvin L.</creatorcontrib><creatorcontrib>Hui, David S. C.</creatorcontrib><creatorcontrib>Tham, Clement C. Y.</creatorcontrib><creatorcontrib>Chan, Paul K. S.</creatorcontrib><creatorcontrib>Pang, Chi Pui</creatorcontrib><creatorcontrib>Chong, Kelvin K. L.</creatorcontrib><title>Ocular surface disturbance in patients after acute COVID‐19</title><title>Clinical &amp; experimental ophthalmology</title><addtitle>Clin Exp Ophthalmol</addtitle><description>Background We investigated the ocular surface disturbances in COVID‐19 patients discharged from the hospital. Methods One hundred and seventy‐nine eyes of 109 healthy participants and 456 eyes of 228 post‐COVID‐19 patients received comprehensive eye examinations; the latter were interviewed with questionnaires on ocular symptoms before and after COVID‐19 diagnosis. Associations of ocular surface manifestations with virological and ophthalmic parameters were evaluated by multivariable mixed linear or logistic regression models. Results Mean interval between COVID‐19 diagnosis and ophthalmic evaluation was 52.23 ± 16.12 days. The severity of meibomian gland dysfunction (MGD) based on clinical staging was higher in post‐COVID‐19 than healthy eyes (1.14 ± 0.67 vs. 0.92 ± 0.68, p = 0.002) and so was ocular surface staining score (0.60 ± 0.69 vs. 0.49 ± 0.68, p = 0.044). Patients requiring supplementary oxygen during hospitalisation had shorter tear break‐up time (β −1.63, 95% CI ‐2.61 to −0.65). Cycle threshold (Ct) value from upper respiratory samples (inversely correlated with viral load) at diagnosis had an OR = 0.91 (95% CI 0.84–0.98) with new ocular surface symptoms 4 weeks after diagnosis. The presence of ocular surface symptoms 1 week prior to COVID‐19 diagnosis showed an OR of 20.89 (95% CI 6.35–68.66) of persistent or new ocular symptoms 4 weeks afterward. Conclusions MGD and ocular surface staining are more common and severe in post‐COVID‐19 patients. Patients with higher viral loads have greater risks of ocular surface symptoms. Patients requiring supplementary oxygen are more likely to show tear film instability. Ocular surface evaluation should be considered 1–3 months following hospital discharge for any COVID‐19 patient.</description><subject>COVID-19</subject><subject>Diagnosis</subject><subject>Eye</subject><subject>Eye examinations</subject><subject>meibomian gland dysfunction</subject><subject>ocular surface</subject><subject>Original</subject><subject>ORIGINAL ARTICLES</subject><subject>Oxygen</subject><subject>Patients</subject><subject>Regression analysis</subject><subject>tear break up time</subject><issn>1442-6404</issn><issn>1442-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kUFOwzAQRS0EoqWw4AIoEhtYpLVjx0kWIKFQoFKlboCt5TgTcJUmxU5A3XEEzshJMKRUgIQ3M5Kf_3zPR-iQ4CFxZ6SgHhKGOd9CfcJY4Cc4ItvrnjPMemjP2jnGOAwo30U9GgYkJpT10dlMtaU0nm1NIRV4ubZNazJZuV5X3lI2GqrGerJowHhStQ146ex-cvn--kaSfbRTyNLCwboO0N3V-Da98aez60l6MfUVY5T7oQpozvMcgGRc4gAAsogyYEQBZkAJidxwDIyGCQNFuXsls4grSCiNcUgH6LzTXbbZAnLlLBlZiqXRC2lWopZa_L6p9KN4qJ9F4tYTs9gJnKwFTP3Ugm3EQlsFZSkrqFsrAu4GJTzExKHHf9B53ZrKfc9RUUQoxiRw1GlHKVNba6DYmCFYfIYiXCjiKxTHHv10vyG_U3DAqANedAmr_5VEOp51kh8O0ZXK</recordid><startdate>202205</startdate><enddate>202205</enddate><creator>Wan, Kelvin H.</creator><creator>Lui, Grace C. Y.</creator><creator>Poon, Ken C. F.</creator><creator>Ng, Susanna S. S.</creator><creator>Young, Alvin L.</creator><creator>Hui, David S. C.</creator><creator>Tham, Clement C. Y.</creator><creator>Chan, Paul K. S.</creator><creator>Pang, Chi Pui</creator><creator>Chong, Kelvin K. L.</creator><general>John Wiley &amp; Sons Australia, Ltd</general><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0307-2256</orcidid><orcidid>https://orcid.org/0000-0003-2587-1323</orcidid></search><sort><creationdate>202205</creationdate><title>Ocular surface disturbance in patients after acute COVID‐19</title><author>Wan, Kelvin H. ; Lui, Grace C. Y. ; Poon, Ken C. F. ; Ng, Susanna S. S. ; Young, Alvin L. ; Hui, David S. C. ; Tham, Clement C. Y. ; Chan, Paul K. S. ; Pang, Chi Pui ; Chong, Kelvin K. L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4436-5c23d6ddee1b6a02eeeb734e41ce04e3117fac0e43594ec36443ab76ce9338053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>COVID-19</topic><topic>Diagnosis</topic><topic>Eye</topic><topic>Eye examinations</topic><topic>meibomian gland dysfunction</topic><topic>ocular surface</topic><topic>Original</topic><topic>ORIGINAL ARTICLES</topic><topic>Oxygen</topic><topic>Patients</topic><topic>Regression analysis</topic><topic>tear break up time</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wan, Kelvin H.</creatorcontrib><creatorcontrib>Lui, Grace C. Y.</creatorcontrib><creatorcontrib>Poon, Ken C. F.</creatorcontrib><creatorcontrib>Ng, Susanna S. S.</creatorcontrib><creatorcontrib>Young, Alvin L.</creatorcontrib><creatorcontrib>Hui, David S. C.</creatorcontrib><creatorcontrib>Tham, Clement C. Y.</creatorcontrib><creatorcontrib>Chan, Paul K. S.</creatorcontrib><creatorcontrib>Pang, Chi Pui</creatorcontrib><creatorcontrib>Chong, Kelvin K. L.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical &amp; experimental ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wan, Kelvin H.</au><au>Lui, Grace C. Y.</au><au>Poon, Ken C. F.</au><au>Ng, Susanna S. S.</au><au>Young, Alvin L.</au><au>Hui, David S. C.</au><au>Tham, Clement C. Y.</au><au>Chan, Paul K. S.</au><au>Pang, Chi Pui</au><au>Chong, Kelvin K. L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocular surface disturbance in patients after acute COVID‐19</atitle><jtitle>Clinical &amp; experimental ophthalmology</jtitle><addtitle>Clin Exp Ophthalmol</addtitle><date>2022-05</date><risdate>2022</risdate><volume>50</volume><issue>4</issue><spage>398</spage><epage>406</epage><pages>398-406</pages><issn>1442-6404</issn><eissn>1442-9071</eissn><abstract>Background We investigated the ocular surface disturbances in COVID‐19 patients discharged from the hospital. Methods One hundred and seventy‐nine eyes of 109 healthy participants and 456 eyes of 228 post‐COVID‐19 patients received comprehensive eye examinations; the latter were interviewed with questionnaires on ocular symptoms before and after COVID‐19 diagnosis. Associations of ocular surface manifestations with virological and ophthalmic parameters were evaluated by multivariable mixed linear or logistic regression models. Results Mean interval between COVID‐19 diagnosis and ophthalmic evaluation was 52.23 ± 16.12 days. The severity of meibomian gland dysfunction (MGD) based on clinical staging was higher in post‐COVID‐19 than healthy eyes (1.14 ± 0.67 vs. 0.92 ± 0.68, p = 0.002) and so was ocular surface staining score (0.60 ± 0.69 vs. 0.49 ± 0.68, p = 0.044). Patients requiring supplementary oxygen during hospitalisation had shorter tear break‐up time (β −1.63, 95% CI ‐2.61 to −0.65). Cycle threshold (Ct) value from upper respiratory samples (inversely correlated with viral load) at diagnosis had an OR = 0.91 (95% CI 0.84–0.98) with new ocular surface symptoms 4 weeks after diagnosis. The presence of ocular surface symptoms 1 week prior to COVID‐19 diagnosis showed an OR of 20.89 (95% CI 6.35–68.66) of persistent or new ocular symptoms 4 weeks afterward. Conclusions MGD and ocular surface staining are more common and severe in post‐COVID‐19 patients. Patients with higher viral loads have greater risks of ocular surface symptoms. Patients requiring supplementary oxygen are more likely to show tear film instability. Ocular surface evaluation should be considered 1–3 months following hospital discharge for any COVID‐19 patient.</abstract><cop>Melbourne</cop><pub>John Wiley &amp; Sons Australia, Ltd</pub><pmid>35218134</pmid><doi>10.1111/ceo.14066</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-0307-2256</orcidid><orcidid>https://orcid.org/0000-0003-2587-1323</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1442-6404
ispartof Clinical & experimental ophthalmology, 2022-05, Vol.50 (4), p.398-406
issn 1442-6404
1442-9071
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9111848
source Wiley Online Library - AutoHoldings Journals
subjects COVID-19
Diagnosis
Eye
Eye examinations
meibomian gland dysfunction
ocular surface
Original
ORIGINAL ARTICLES
Oxygen
Patients
Regression analysis
tear break up time
title Ocular surface disturbance in patients after acute COVID‐19
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-10T10%3A29%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocular%20surface%20disturbance%20in%20patients%20after%20acute%20COVID%E2%80%9019&rft.jtitle=Clinical%20&%20experimental%20ophthalmology&rft.au=Wan,%20Kelvin%20H.&rft.date=2022-05&rft.volume=50&rft.issue=4&rft.spage=398&rft.epage=406&rft.pages=398-406&rft.issn=1442-6404&rft.eissn=1442-9071&rft_id=info:doi/10.1111/ceo.14066&rft_dat=%3Cproquest_pubme%3E2633896501%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2677130012&rft_id=info:pmid/35218134&rfr_iscdi=true